CytomX Therapeutics (CTMX) Income from Non-Controlling Interests (2015 - 2026)
CytomX Therapeutics (CTMX) posted Income from Non-Controlling Interests of -$9000.0 for Q1 2026, down 112.68% on a QoQ basis from $71000.0 in Q3 2025, and up 67.86% year-over-year from -$5361.7 in Q1 2025.
CytomX Therapeutics (CTMX) Income from Non-Controlling Interests (2015 - 2026) Analysis & Trends
CytomX Therapeutics' Income from Non-Controlling Interests history runs 12 years deep, the most recent figure standing at -$9000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 67.86% year-over-year to -$9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68000.0 (up 655.56% YoY) and the FY2024 annual result came in at -$68000.0, down 180.0% from the prior year.
- Income from Non-Controlling Interests was -$9000.0 for Q1 2026 at CytomX Therapeutics, down from $71000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $805000.0 in Q4 2022 and bottomed at -$677000.0 in Q1 2022.
- A 5-year average of $21062.5 and a median of $7500.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 891.89% in 2022, while the deepest fall reached 17025.0% in 2022.
- CytomX Therapeutics' Income from Non-Controlling Interests stood at $805000.0 in 2022, then slumped by 80.37% to $158000.0 in 2023, then sank by 108.23% to -$13000.0 in 2024, then surged by 646.15% to $71000.0 in 2025, then slumped by 112.68% to -$9000.0 in 2026.
- Business Quant data shows CTMX's Income from Non-Controlling Interests at -$9000.0 in Q1 2026, $71000.0 in Q3 2025, and $34000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,000.00 |
| Sep 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | -28,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | -105,000.00 |
| Dec 31, 2023 | 158,000.00 |
| Sep 30, 2023 | -98,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | 805,000.00 |
| Sep 30, 2022 | 367,000.00 |
| Jun 30, 2022 | -243,000.00 |
| Mar 31, 2022 | -677,000.00 |
| Dec 31, 2021 | -294,000.00 |
| Sep 30, 2021 | 37,000.00 |
| Jun 30, 2021 | 58,000.00 |
| Mar 31, 2021 | 4,000.00 |